X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Cancer Risk Leads Pfizer Recall Blood Pressure Drug From US

Content Team by Content Team
28th April 2022
in News
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

Pfizer’s recall saga has now reached the United States, after elevated concentrations of potential carcinogens forced the company to pull multiple products in Canada. After testing revealed quantities of a nitrosamine—Nnitroso-quinapril—above daily recommended limits, Pfizer is recalling five lots of Accupril pills, commonly known as quinapril HCL.

Nitrosamines are found in a wide range of foods, including cured and barbecued meats, dairy products, and vegetables. Everybody is susceptible to nitrosamines in some way, and cancer is only a result of long-term exposure to high levels of nitrosamines. Accupril is a blood pressure medication that has been licenced for the treatment of hypertension. According to Pfizer, it’s also prescribed to treat heart issues as an add-on therapy to diuretics or digitalis.

Pfizer said it had not acquired any safety evidence relating to the recalled medicines as of the week ending 23rd April 22.  Accupril has a 30-year safety track history, according to the company, and it believes the benefits of the drug exceed the dangers based on current research.

Although long-term consumption of Nnitroso-quinapril has been linked to an elevated cancer risk in humans, there is no imminent threat to patients using this drug, Pfizer said in a statement on the FDA’s website. Patients who are presently taking the drugs should discuss alternative therapies with their physician or health care provider. Between December 2019 and April 2022, Pfizer delivered the five Accupril lots across the United States and Puerto Rico.

The 90-count bottles of 10-, 20-, and 40-mg Accupril were slated to expire between the end of March and May of next year. In recent years, nitrosamines have been implicated in a slew of recalls, most prominently of valsartan blood pressure medications and metformin diabetes medications. Pfizer’s Chantix recall in 2021 was likewise driven by an excess of nitrosamines. Meanwhile, Pfizer has also recalled two different batches of blood pressure medicine in Canada because of nitrosamine concerns.

Meanwhile, in Canada, Pfizer recently recalled two separate blood pressure medication batches due to nitrosamine concerns. These medications were Accuretic, for which Pfizer withdrew all lots in Canada, and Inderal, for which Pfizer recalled 15 batches.

Previous Post

FDA Seeks To Know How Prescription Drug Risks Are Weighed

Next Post

With Biologics Spread Catalent Buys NJ Cell Therapy Plant

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
Catalent To Open New Clinical Supply Facility In San Diego

With Biologics Spread Catalent Buys NJ Cell Therapy Plant

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In